GenVec, Inc.

Development of gene-based medicines for the treatment of cancer, cardiovascular disease and vision loss

GenVec is a biopharmaceutical company developing gene-based medicines for the treatment of major diseases, such as cancer and cardiovascular disease. GenVec merged with Diacrin Inc. in 2001, a company developing transplantation therapies based on porcine liver cells. GenVec is traded on the New York Stock Exchange under the ticker symbol GNVC.

Paul H. Fischer, Ph.D., President and CEO
Douglas J. Swirsky, CFO, Treasurer and Corporate Secretary
Bryan T. Butman, Ph.D., Senior VP of Vector Operations
C. Richter King, Ph.D., Senior VP of Research
Milan Kovacevic, M.D., Ph.D., President of Clinical Operations
Mark O. Thornton, M.D., Ph.D., Senior VP of Product Development

Zola P. Horovitz, Ph.D., Chairman
Wayne T. Hockmeyer, Ph.D.
William N. Kelley, M.D.
Joshua Ruch
Marc R. Schneebaum

65 West Watkins Mill Road
Gaithersburg, MD 20878
USA
Phone: +1-240-632-0740
Fax: +1-240-632-0735

The proprietary adenovector technology allows the local administration to target tissues. The company has several lead products. These include: BIOBYPASS® PVD for the treatment of peripheral vascular diesease and BIOBYPASS CAD for the treatment of coronary artery disease. TNFerade™ is a proprietary gene therapy product candidate, for the treatment of cancer in conjunction with radiation therapy.

In addition, other product candidates include vaccines for HIV, SARS, malaria and the Dengue virus; PDEF to prevent blindness and cell transplantation therapies.
GenVec has a broad intellectual property portfolio including patents and patent applications (currently approximately 380) covering technologies for rapid product generation and selection, product specificity, highly efficient gene transfer transfer systems, drug administration devices, methods for treating a variety of diseases, therapeutic genes, process development, etc.

GenVac is conducting two Phase II clinical trials with TNFerade. First one to compare TNFerade plus standard of care therapy (defined as infusion 5-FU and radiation therapy, followed by gemcitabine maintenance therapy) versus standard of care therapy in the treatment of locally advanced, unresectable pancreatic cancer. Second one for the treatment of rectal cancer.
BIOBYPASS® is currently tested in a Phase IIB clinical trial to evaluate its potential use in the treatment of severe coronary artery disease (CAD).

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.